Literature DB >> 8971741

Cannabinoid receptor-mediated inhibition of dopamine release in the retina.

E Schlicker1, J Timm, M Göthert.   

Abstract

The possible occurrence of cannabinoid (CB) receptors was studied on superfused guinea-pig retinal discs preincubated with [3H]dopamine or [3H]noradrenaline. Tritium overflow was evoked either electrically (3 Hz) or by re-introduction of Ca2+ 1.3 mM after superfusion with Ca(2+)-free medium containing K+ 30 mM. The accumulation of [3H]dopamine ([3H]DA) and [3H]noradrenaline ([3H]NA) was inhibited by the selective inhibitor of the neuronal dopamine transporter GBR-12909 (pIC50% 7.29 and 7.41, respectively) but not by the selective inhibitor of the neuronal noradrenaline transporter desipramine (1 microM). The electrically or Ca(2+)-evoked tritium overflow in retinal discs preincubated with [3H]DA or [3H]NA was reduced by the CB receptor agonists CP-55,940 and WIN 55,212-2 (pIC50% in discs preincubated with [3H]NA, electrical stimulation: 7.03 and 6.70, respectively) but not affected by the inactive S(-)enantiomer of the latter, WIN 55,212-3 (up to 10 microM). The concentration-response curve of WIN 55,212-2 was shifted to the right by the CB1 receptor antagonist SR 141716 (apparent pA2: 8.29) which, by itself, increased the evoked overflow. The facilitatory effect of SR 141716 was not affected by GBR-12909 and the dopamine receptor antagonist haloperidol. In conclusion, the dopaminergic neurones of the guinea-pig retina can be labelled by both [3H]DA and [3H]NA. Transmitter release from the dopaminergic neurones is inhibited by activation of cannabinoid receptors of the CB1 type, which appear to be tonically activated by an endogenous CB receptor ligand.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971741     DOI: 10.1007/BF00166907

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  19 in total

Review 1.  Pharmacology of cannabinoid receptors.

Authors:  A C Howlett
Journal:  Annu Rev Pharmacol Toxicol       Date:  1995       Impact factor: 13.820

2.  Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures.

Authors:  M Shen; T M Piser; V S Seybold; S A Thayer
Journal:  J Neurosci       Date:  1996-07-15       Impact factor: 6.167

Review 3.  Modulation of neurotransmitter release by presynaptic autoreceptors.

Authors:  K Starke; M Göthert; H Kilbinger
Journal:  Physiol Rev       Date:  1989-07       Impact factor: 37.312

4.  In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.

Authors:  D R Compton; M D Aceto; J Lowe; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1996-05       Impact factor: 4.030

5.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; M Héaulme; D Shire; B Calandra; C Congy; S Martinez; J Maruani; G Néliat; D Caput
Journal:  FEBS Lett       Date:  1994-08-22       Impact factor: 4.124

6.  The evolution of retinal vascularization in mammals. A comparison of vascular and avascular retinae.

Authors:  J Chase
Journal:  Ophthalmology       Date:  1982-12       Impact factor: 12.079

7.  Determination and characterization of a cannabinoid receptor in rat brain.

Authors:  W A Devane; F A Dysarz; M R Johnson; L S Melvin; A C Howlett
Journal:  Mol Pharmacol       Date:  1988-11       Impact factor: 4.436

8.  Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.

Authors:  A N Gifford; C R Ashby
Journal:  J Pharmacol Exp Ther       Date:  1996-06       Impact factor: 4.030

9.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

10.  Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake.

Authors:  R E Heikkila; L Manzino
Journal:  Eur J Pharmacol       Date:  1984-08-17       Impact factor: 4.432

View more
  20 in total

1.  Alterations to global but not local motion processing in long-term ecstasy (MDMA) users.

Authors:  Claire White; John Brown; Mark Edwards
Journal:  Psychopharmacology (Berl)       Date:  2014-01-19       Impact factor: 4.530

2.  Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system.

Authors:  A Straiker; N Stella; D Piomelli; K Mackie; H J Karten; G Maguire
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

3.  Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line.

Authors:  A B El-Remessy; M Rajesh; P Mukhopadhyay; B Horváth; V Patel; M M H Al-Gayyar; B A Pillai; P Pacher
Journal:  Diabetologia       Date:  2011-03-04       Impact factor: 10.122

4.  Architecture of cannabinoid signaling in mouse retina.

Authors:  Sherry Shu-Jung Hu; Andy Arnold; Jacqueline M Hutchens; Josh Radicke; Benjamin F Cravatt; Jim Wager-Miller; Ken Mackie; Alex Straiker
Journal:  J Comp Neurol       Date:  2010-09-15       Impact factor: 3.215

5.  Identification of the dopamine autoreceptor in the guinea-pig retina as D(2) receptor using novel subtype-selective antagonists.

Authors:  B Weber; E Schlicker; P Sokoloff; H Stark
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

6.  Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta.

Authors:  T Schultheiss; K Flau; M Kathmann; M Göthert; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-09-30       Impact factor: 3.000

7.  Prostaglandins of the E series inhibit monoamine release via EP3 receptors: proof with the competitive EP3 receptor antagonist L-826,266.

Authors:  J Günther; K Schulte; D Wenzel; B Malinowska; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-10       Impact factor: 3.000

8.  Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex.

Authors:  M Steffens; C Engler; J Zentner; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

Review 9.  Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

Authors:  Hester van Diepen; Eberhard Schlicker; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-25       Impact factor: 3.000

Review 10.  Endocannabinoids in the retina: from marijuana to neuroprotection.

Authors:  Stephen Yazulla
Journal:  Prog Retin Eye Res       Date:  2008-08-03       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.